Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory <i>BRAF</i> V600-Mutant Pediatric High-Grade Glioma.

DR, Hargrave; K, Terashima; J, Hara; UR, Kordes; SA, Upadhyaya; F, Sahm; E, Bouffet; RJ, Packer; O, Witt; L, Sandalic; A, Kieloch; M, Russo; KJ, Cohen

doi:10.1200/jco.23.00558

Public

Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory <i>BRAF</i> V600-Mutant Pediatric High-Grade Glioma.

Shared by NobleBlocks on Aug 29, 2023 • 12:00 AM UTC

Authors:

Hargrave DR

Terashima K

Hara J

Abstract

<h4>Purpose</h4><i>BRAF</i> V600 mutation is detected in 5%-10% of pediatric high-grade gliomas (pHGGs), and effective treatments are limited. In previous trials, dabrafenib as monotherapy or in combination with trametinib demonstrated activity in children and adults with relapsed/refractory <i>BRAF...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!